The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FATE | -52.32% | -96.54% | -48.96% | -77% |
| S&P | +14.84% | +96.04% | +14.41% | +297% |
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
The biotech has an interesting pipeline, but it's all early stage products.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.91M | -71.8% |
| Gross Profit | -$1.37M | -166.8% |
| Gross Margin | -71.89% | -102.2% |
| Market Cap | $128.39M | -65.6% |
| Market Cap / Employee | $0.71M | 0.0% |
| Employees | 181 | 0.0% |
| Net Income | -$34.07M | 11.3% |
| EBITDA | -$33.69M | 16.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.25M | 11.7% |
| Accounts Receivable | $1.40M | 33.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $75.68M | -19.4% |
| Short Term Debt | $5.66M | -14.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.10% | -6.5% |
| Return On Invested Capital | -38.52% | -2.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$25.95M | 19.8% |
| Operating Free Cash Flow | -$24.59M | 23.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.10 | 0.52 | 0.28 | 0.45 | -49.19% |
| Price to Sales | 30.65 | 14.26 | 7.01 | 15.67 | -49.90% |
| Price to Tangible Book Value | 1.10 | 0.52 | 0.28 | 0.45 | -49.19% |
| Enterprise Value to EBITDA | -4.49 | -0.01 | 1.68 | 0.26 | -105.79% |
| Return on Equity | -46.6% | -54.2% | -49.2% | -52.1% | 23.76% |
| Total Debt | $98.98M | $85.27M | $83.33M | $81.33M | -19.12% |
FATE earnings call for the period ending October 31, 2021.
FATE earnings call for the period ending June 30, 2021.
FATE earnings call for the period ending March 31, 2021.
FATE earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
